Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F10%3A10213246" target="_blank" >RIV/61989592:15110/10:10213246 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/10:#0000398

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma

Popis výsledku v původním jazyce

We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI.lt.2,8% (median overall survival 30 vs 12 months) with a borderline significance (p=0,06). However, after approximately 40 months from diagnosis the curves merged, suggesting the influence of novel drugs.In patients treated with conventional chemotherapy only, the difference maintained significant even after 40 months (median overall survival 25 vs 10 months, p=0,015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in al

Název v anglickém jazyce

Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma

Popis výsledku anglicky

We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI.lt.2,8% (median overall survival 30 vs 12 months) with a borderline significance (p=0,06). However, after approximately 40 months from diagnosis the curves merged, suggesting the influence of novel drugs.In patients treated with conventional chemotherapy only, the difference maintained significant even after 40 months (median overall survival 25 vs 10 months, p=0,015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in al

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR9500" target="_blank" >NR9500: Angiogeneza, kinetika plasmocytů, parametry mikroprostředí kostní dřeně a metabolismu skeletu v diagnostice monoklonální gamapatie nejistého významu a iniciálních stádií mnohočetného myelomu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neoplasma

ISSN

0028-2685

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—